CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Study Indication or Disease
Study Name
M14-212 AbbVie_IU_icons_outlined_v3 Acute Myelogenous Leukemia (AML) Phase 2 A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)
M13-364 AbbVie_IU_icons_outlined_v3 Non-Hodgkin lymphoma Phase 1 A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199